New CAR t therapy targets Hard-to-Treat gut cancers
Disease control
Recruiting now
This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack canc…
Phase: PHASE1, PHASE2 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:54 UTC